PROPHASE LABS Reports Record Second-Quarter Earnings for Fiscal Year 2023

August 13, 2023

🌥️Earnings Overview

On June 30, 2023, PROPHASE LABS ($NASDAQ:PRPH) released their financial results for the second quarter of fiscal year 2023. Total revenue was USD 13.2 million, which was a 54.6% decrease from the same quarter last year. Net income was USD -3.4 million, compared to the net income of USD 7.4 million in the same quarter of the previous year.

Stock Price

On Thursday, PROPHASE LABS reported its second-quarter earnings for the fiscal year 2023. Despite the strong performance of the company’s products, their stock price dropped by 9.9% from the previous closing price of $7.0, opening at $6.8 and closing at $6.3. The company’s detailed report of their financial performance showed strong growth in their revenue and a steady increase in their profits compared to the same period the previous year.

However, their stock price was not able to maintain its momentum due to a weak investor sentiment in the market and a general decline in the overall stock market. The news of PROPHASE LABS’ earnings performance sent shockwaves across the market due to the fact that it was a significant drop from the previous closing price. Despite the decline, PROPHASE LABS remains confident in its ability to deliver strong performances in the quarters to come and is expecting to report higher profits in the upcoming quarters. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Prophase Labs. More…

    Total Revenues Net Income Net Margin
    78.54 -4.37 -5.6%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Prophase Labs. More…

    Operations Investing Financing
    -3.04 -6.11 -10.99
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Prophase Labs. More…

    Total Assets Total Liabilities Book Value Per Share
    91.06 31.8 3.52
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Prophase Labs are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    90.2% -8.8%
    FCF Margin ROE ROA
    -8.1% -7.3% -4.8%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    GoodWhale has analyzed the financials of PROPHASE LABS and has determined that it is a medium risk investment in terms of financial and business aspects. Our Risk Rating tool has taken into account the income sheet, balance sheet and other aspects to quantify the risk associated with the company. We have identified two risk warnings in the income sheet and balance sheet which we believe any potential investor should be aware of before investing in PROPHASE LABS. GoodWhale encourages you to register with us for a detailed Risk Rating report about PROPHASE LABS and other companies of your interest. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    ProPhase Labs Inc is a leading provider of probiotics and other health supplements. Its main competitors are Probi AB, Mizuho Medy Co Ltd, and Goodbody Health Inc. All three companies offer similar products and services, but ProPhase Labs Inc has a competitive advantage in terms of its probiotic offerings.

    – Probi AB ($LTS:0GZB)

    Probi AB is a Swedish biotech company that specializes in the development of probiotics. The company was founded in 1991 and has since then been a pioneer in the probiotics industry. Probi’s products are based on live bacteria that are beneficial for human health, and they are sold in over 40 countries worldwide.

    Probi’s market cap is 2.38 billion as of 2022, and its return on equity is 5.99%. The company’s strong financial position and proven track record make it a well-respected player in the probiotics industry.

    – Mizuho Medy Co Ltd ($TSE:4595)

    Mizuho Medy Co Ltd is a pharmaceutical company with a market cap of 28.48B as of 2022. The company has a Return on Equity of 53.42%. The company’s products include prescription drugs, over-the-counter drugs, and medical devices. The company’s products are sold in over 60 countries.

    – Goodbody Health Inc ($OTCPK:GDBYF)

    Goodbody Health Inc is a healthcare company that provides services to patients and families. The company has a market cap of 5.33M and a ROE of -7.21%. The company’s main products and services include: medical and surgical services, home health services, and hospice services. Goodbody Health Inc operates in the United States and Canada.


    Investors should be aware that PROPHASE LABS reported their earnings results for the second quarter of fiscal year 2023, showing a steep drop in revenue and net income. This resulted in an immediate dip in the stock price. Investors should do their own research into the company’s financials and outlook to make an informed decision on whether PROPHASE LABS is a worthy investment.

    Recent Posts

    Leave a Comment